QURE Stock Recent News

UniQure (QURE) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of $2.97. This compares to loss of $0.84 per share a year ago.

Wednesday, uniQure announced interim phase 1/2 results for its experimental Huntington's disease gene therapy. Results from the high-dose cohort raised more questions than they answered.

uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.

uniQure reported interim data from a phase 1/2 study of AMT-130 in treating Huntington's disease. The results for the low dose of the gene therapy were promising.

uniQure's strong financial performance and remarkable revenue growth highlight the company's continued upward trajectory, making it a promising investment opportunity. Innovative gene therapies such as HEMGENIX for hemophilia B and AMT-130 for Huntington's disease pave the way for a complete transformation of current medical treatments.

UniQure (QURE) came out with a quarterly loss of $1.63 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1 per share a year ago.

uniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Hemgenix was approved by FDA. uniQure appears undervalued based on the value of milestones and royalties due to the company.

Recent approval of Hemgenix therapy creates alpha opportunity. Market has responded swiftly and we see upside targets of $31.5 and then $49.

FDA approval of uniQure N.V.'s Hemgenix for the treatment of adults with Hemophilia B achieved. There is potential to receive European approval of Hemgenix for the treatment of adults with Hemophilia B in 2023 on standard review timeline.